Orion Oyj (OTCMKTS:ORINY) Hits New 12-Month High - Should You Buy?

Orion Oyj (OTCMKTS:ORINY - Get Free Report)'s stock price reached a new 52-week high during trading on Monday . The company traded as high as $31.32 and last traded at $31.32, with a volume of 250 shares changing hands. The stock had previously closed at $30.63.

Wall Street Analyst Weigh In

Separately, Nordea Equity Research downgraded Orion Oyj to a "hold" rating in a research note on Tuesday, February 4th.

Orion Oyj Price Performance

The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.41 and a current ratio of 2.42. The firm has a fifty day simple moving average of $29.06 and a two-hundred day simple moving average of $25.97. The firm has a market cap of $8.84 billion, a PE ratio of 24.86 and a beta of 0.15.

Orion Oyj (OTCMKTS:ORINY - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The company reported $0.23 earnings per share (EPS) for the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. The company had revenue of $373.03 million for the quarter. Equities analysts predict that Orion Oyj will post 1.18 EPS for the current fiscal year.

Orion Oyj Increases Dividend

The business also recently disclosed a dividend, which was paid on Tuesday, April 29th. Shareholders of record on Monday, April 7th were given a dividend of $0.4478 per share. The ex-dividend date was Monday, April 7th. This is an increase from Orion Oyj's previous dividend of $0.24. Orion Oyj's dividend payout ratio is 24.43%.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.